Skip to main content
Scientists from the University Hospital Bonn and the University of Bonn discover an important membrane transport mechanism in pathogenic bacteria. PD Dr. Gregor Hagelueken (left) and Philipp Hendricks (right) are part of the research team.

News categories: Publication

Scientists discover a membrane transport system of bacteria

Researchers from the University Hospital of Bonn and the University of Bonn in collaboration with the University of York studied an important class of bacterial membrane transporters and their interaction with soluble substrate binding proteins. They found that transporter and its substrate binding protein adapt to each other rapidly and that these interactions are crucial for the working mechanism of the transporter system.

Membrane transport mechanisms are crucial for the survival of pathogenic bacteria as they, for instance, allow resistance against the host’s immune system. Thus, it is important to understand the underlying molecular mechanism of bacterial membrane transporters and ultimately to find ways to modulate or block them.

A membrane transport mechanism working like a molecular freight elevator

Pathogenic bacteria such as Haemophilus influenzae use tripartite ATP-independent periplasmic (TRAP) transporters to facilitate the uptake of sialic acid into the bacterial cell. Sialic acid is a small sugar molecule that is abundant in our tissues. H. influenzae bacteria can harvest the sialic acid and incorporate it into their own cell wall, thereby camouflaging themselves from the host’s immune system. The TRAP transporter comprises of two transmembrane domains that span the inner membrane of the bacterium and is supported by a substrate binding protein (SBP). Once the SBP encounters a sialic acid molecule, it undergoes a large conformational change, tightly binds the sialic acid and transports it to the TRAP transporter. In the next step, the transporter grabs the sialic acid from the SBP and translocates it across the membrane into the bacterial cell.

The TRAP transporter system can undergo distinct conformational changes


Each of the two proteins can adopt two different conformational states, the open- and closed state of the SBP and the inward- and outward-facing state of the transporter. The research team led by PD Dr. Gregor Hagelueken from the Institute of Structural Biology at the University Hospital of Bonn who is supported by the ImmunoSensation2 Cluster of Excellence and the Transdisciplinary Research Area (TRA) “Life & Health” suspected that there is a ”conformational coupling” between the TRAP transporter and its SBP, meaning that the closed state of the SBP selectively recognizes the inward-facing state of the transporter, while the open state of the SBP preferably interacts with the outward-facing state of the transporter. The team was able to lock both the transporter and its SBP in their conformational states by employing disulfide engineering and found that TRAP transporter and SBP could indeed recognize the conformational state of the other.
By using biophysical and structural biology experiments, as well as advanced microscopy techniques provided in collaboration with Prof. Dr. Ulrich Kubitscheck from the Clausius Institute of Physical and Theoretical Chemistry at the University of Bonn, it was possible to precisely observe the working mechanism of TRAP transporter and the SBP. The researchers incorporated the TRAP transporter into artificial membranes and employed single-molecule fluorescence microscopy to observe the interaction between TRAP transporter and SBP in real time, giving insights into the working principle of the transporter system.
The interesting study was recently published in Nature Communications and sheds light on the structural properties and therefore the working mechanism of SBP-dependent bacterial membrane transport systems.

Publication

Martin F. Peter, Jan A. Ruland, Yeojin Kim, Philipp Hendricks et al. (2024)

Conformational coupling of the sialic acid TRAP transporter HiSiaQM with its substrate binding protein HiSiaP

Nature Communications

DOI: https://doi.org/10.1038/s41467-023-44327-3

Contact

PD Dr. Gregor Hagelueken

Institute of Structural Biology
University Hospital Bonn (UKB)
Immunosensation2 Cluster of Excellence & TRA "Life & Health" at University of Bonn

Phone: +49 (0)228 287-51200
E-mail: hagelueken@uni-bonn.de

Related news

News Icon

News categories: Publication

Malaria Causes Permanent Damage to Phagocytes in the Spleen

Macrophages formed in the bone marrow can only assume the function of embryonal phagocytes, or “scavenger cells,” to a certain degree according to a study by the University of Bonn and the Peter Doherty Institute for Infection and Immunity at the University of Melbourne. The researchers have demonstrated that malaria infection causes permanent damage to resident CD163 macrophages in the spleen, which are responsible for cleaning the blood, recycling iron and communicating with other cells involved in the body’s immune response.
View entry
Tracking glioblastoma cell spread in human brain tissue

News categories: Publication

Core2Edge: How tumor cells conquer the brain

Glioblastoma is an aggressive brain tumor that infiltrates deep into the surrounding brain tissue. Even after surgery, tumor cells remain in the brain and the tumor recurs. Bonn researchers have now developed Core2Edge, a model based entirely on human tissue that captures these hard-to-access infiltration zones at the tumor margin. The model enables investigation of the invasive front and direct assessment of new drug candidates in human tissue - without the need for animal testing. The study of the Brain Tumor Translational Research Group has now been published in Nature Protocols.
View entry
Mikrochip zur Wiederherstellung zentralen Sehvermögens bei fortgeschrittener Makuladegeneration.

News categories: Publication

Approval of a Novel Retinal Implant Technology

A novel retinal implant is offering people with geographic atrophy the opportunity to regain part of their central vision for the first time. Geographic atrophy is a severe late stage of age-related macular degeneration. An international research team led by Prof. Frank G. Holz of the UKB and the University of Bonn demonstrated in an international clinical trial that the majority of participants experienced significant improvements in visual acuity. The novel retinal implant technology has now received approval for routine clinical use in Europe, making it available beyond clinical trials.
View entry

Back to the news overview